Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul 19;3(7):100691.
doi: 10.1016/j.xcrm.2022.100691.

Neoadjuvant therapy gains FDA approval in non-small cell lung cancer

Ticiana A Leal  1 , Suresh S Ramalingam  2
Affiliations
Comment

Neoadjuvant therapy gains FDA approval in non-small cell lung cancer

Ticiana A Leal et al. Cell Rep Med. .

Abstract

Forde et al.1 reported on a randomized clinical trial (CheckMate 816) and showed that neoadjuvant therapy with nivolumab plus chemotherapy led to improved event-free survival and pathological complete response rate in patients with resectable non-small cell lung cancer (NSCLC).

Trial registration: ClinicalTrials.gov NCT04025879.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests S.S.R. is a part of the consultancy/advisory board for Amgen, BMS, Astra Zeneca, Merck, Lilly, Genmab, Eisai, and GSK and provides research support to institutions for Amgen, Astra Zeneca, BMS, Advaxis, Pfizer, Genmab, Merck, and GSK. T.A.L. is a part of the consultancy/advisory board for Merck, AstraZeneca, Daiichi-Sankyo, Janssen, Takeda, EMD Serono, Eisai, Novocure, Roche, Amgen, and Regeneron.

Comment on

  • Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
    Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Forde PM, et al. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. N Engl J Med. 2022. PMID: 35403841 Free PMC article. Clinical Trial.

References

    1. Forde P.M., Spicer J., Lu S., Provencio M., Mitsudomi T., Awad M.M., Felip E., Broderick S.R., Brahmer J.R., Swanson S.J., et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 2022;386:1973–1985. doi: 10.1056/nejmoa2202170. - DOI - PMC - PubMed
    1. NSCLC Meta-analyses Collaborative Group. Auperin A., Higgins J.P., Higgins J.P., Johnson D.H., Le Chevalier T., Le Pechoux C., Parmar M.K.B., Pignon J.P., Souhami R.L., Stephens R.J., et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267–1277. doi: 10.1016/S0140-6736(10)60059-1. - DOI - PMC - PubMed
    1. NSCLC Meta-analysis Collaborative Group Preoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383:1561–1571. doi: 10.1016/S0140-6736(13)62159-5. - DOI - PMC - PubMed
    1. Forde P., Chaft J., Smith K. Neoadjuvant PD-1 Blockade in resectable lung cancer. N. Engl. J. Med. 2018;386:e14. - PubMed
    1. Provencio M., Nadal E., Insa A., Garcia-Campelo M.R., Casal-Rubio J., Domine M., Majem M., Rodriguez-Abreu D., Martinez-Marti A., De Castro Carpeno J., et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1413–1422. doi: 10.1016/s1470-2045(20)30453-8. - DOI - PubMed

MeSH terms

Substances

Associated data